Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets

Q: How long will it take to read this news story?

The story "Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets" has 198 words across 8 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets" was covered 13 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 320 news stories per day. It's most recent story was published 7 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23765571</li><li>URL: https://beamstart.com/news/marksans-pharma-gets-usfda-nod-17322815087867</li></ul>

Business Standard Logo Business Standard 13h ago

Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets - Business Standard

Quick Summary:

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Loratadine tablets indicated in the treatment of allergic rhinitis.

The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Loratadine tablets of strength 10 mg, Marksans Pharma said in a regulatory filing.

Loratadine tablets are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use.